Congressional Offices Consider Making Xylazine a Controlled Substance

January 27, 2023 — 

With illicit xylazine increasingly showing up in street drugs that pose grave risks to human users, government policymakers are discussing making it a controlled substance. The AVMA is closely engaged with the relevant congressional offices and committees, working to maintain veterinary access to this important drug.

Given both the scale of the opioid crisis and the severe consequences for people using narcotics containing xylazine, it is probable that Congress and the DEA will move ahead with plans to schedule xylazine as a controlled substance.

Read more about the problem and what AVMA is doing to mitigate disruption at AVMA

For continuing updates on this and other advocacy-related issues, subscribe to receive the free AVMA Advocate newsletter.

[Source: AVMA 26 January 2023]